ST人福：子公司盐酸纳布啡注射液上市许可申请获受理

Group 1 - The core point of the article is that ST Renfu (600079.SH) announced that its subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has received the acceptance notice for the drug registration application of Nalbuphine Hydrochloride Injection from the National Medical Products Administration [1] - The approved indication for this drug is as an analgesic for anesthesia induction during combined anesthesia and postoperative analgesia [1] - Yichang Renfu obtained clinical trial approval for the drug in September 2022, specifically for its use in pain management for patients in intensive care units (ICU) [1]